Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Ascendis Pharma

ASNDNasdaqBiotechnologyHellerup, DKLarge capWebsite ↗
  • Russell 1000

What Ascendis Pharma is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Latest earnings call or results release (August 13, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
  • Insiders were net sellers in Q3 2026: $0.4 million on the open market.SEC Form 4
  • 311 institutional managers reported a position at June 30, 2026 (+37 on the quarter before).SEC Form 13F

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Ascendis Pharma yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

What the company says

Business

Ascendis Pharma: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.60Data to Aug 2026
ImageDataPalanor calculation
Business

Ascendis Pharma: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Aug 2026
ImageDataPalanor calculation

Hiring and ownership

Business

Ascendis Pharma: H-1B filings certified

Labor Condition Applications by quarter received

0.0Data to Mar 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Ascendis Pharma: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$0.4MData 22 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Ascendis Pharma: institutional holders

Managers reporting a position on Form 13F, by quarter

311.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 19, 2026Lobbying
    Lobbying report (ASCENDIS PHARMA, LLC)third_quarter 2026 · $0.2 million
  2. Sep 29, 2026Patent
    Patent granted: AUTO INJECTOR WITH CARTRIDGE LOCKING SYSTEMUS 12746335
  3. Jul 20, 2026Lobbying
    Lobbying report (ASCENDIS PHARMA, INC.)second_quarter 2026 · $0.2 million
  4. Jul 20, 2026Lobbying
    Lobbying report (RUBICON ADVISORS, LLC)second_quarter 2026 · $0.1 million
  5. Jun 9, 2026Patent
    Patent granted: TREATMENT OF INFECTIONSUS 12648997
  6. Apr 23, 2026Lobbying
    Lobbying report (RUBICON ADVISORS, LLC)first_quarter 2026 · $0.1 million
  7. Apr 17, 2026Lobbying
    Lobbying report (ASCENDIS PHARMA, INC.)first_quarter 2026 · $0.3 million
  8. Apr 7, 2026Patent
    Patent granted: DEGRADABLE HYALURONIC ACID HYDROGELSUS 12594345
  9. Jan 20, 2026Lobbying
    Lobbying report (ASCENDIS PHARMA, INC.)fourth_quarter 2025 · $0.2 million
  10. Jan 18, 2026Lobbying
    Lobbying report (RUBICON ADVISORS, LLC)fourth_quarter 2025 · $0.1 million
  11. Jan 6, 2026Patent
    Patent granted: AUTO INJECTOR WITH RECONSTITUTION HANDLING SUPPORTUS 12514983
  12. Oct 21, 2025Lobbying
    Lobbying report (RUBICON ADVISORS, LLC)third_quarter 2025 · $0.1 million
  13. Aug 12, 2025Patent
    Patent granted: AUTO INJECTOR WITH CHARGER SAFETYUS 12383676

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Amgen AMGN$38.1B$10.2BJun 30, 2026
Arrowhead Pharmaceuticals ARWR$0.7B−$0.1BJun 30, 2026
Axsome Therapeutics AXSM$0.8B−$0.1BJun 30, 2026
Biogen BIIB$9.9B$2.4BMar 31, 2026
Caris Life Sciences CAI$1.0B$0.1BJun 30, 2026
Exelixis EXEL$2.4B$1.2BJul 3, 2026
Gilead Sciences GILD$30.5B$12.9BJun 30, 2026
Halozyme HALO$1.7B$0.8BJun 30, 2026

Identity

SEC CIK
1612042
LEI
549300B66JN3W3J8GH73
Wikidata
Q104479983

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.